Document Detail


Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus.
MedLine Citation:
PMID:  18463034     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the 1-year efficacy and safety of treatment with exenatide in combination with insulin (a use not approved by the US Food and Drug Administration). METHODS: Electronic medical records of 3 private-practice endocrinologists were reviewed to identify patients with type 2 diabetes mellitus (T2DM) receiving insulin who subsequently began exenatide therapy. Patients' baseline hemoglobin A1c (A1C) levels, weights, lipid profiles, blood pressures, and medication utilization were compared with corresponding data obtained after a minimal duration of 12 months. RESULTS: We identified 134 patients with T2DM initiating exenatide therapy in combination with insulin between April 2005 and April 2006. One-year follow-up information was available for 124 patients. Exenatide use resulted in a significant 0.87% reduction in A1C (P<.001), despite a 45% discontinuation of premeal insulin use (P<.001), a 9-U reduction in mean premeal insulin doses (P = .0066), a reduction in the median number of daily insulin injections from 2 to 1 (P = .0053), and a 59% discontinuation rate of sulfonylurea use (P = .0088). Exenatide use was associated with a mean weight loss of 5.2 kg (P<.001), with 72% of evaluable patients losing weight. Forty-eight patients (36%) discontinued exenatide therapy during the first year, primarily attributable to gastrointestinal intolerance. Fourteen patients (10%) experienced hypoglycemia, most of which was mild. CONCLUSION: Exenatide in combination with insulin in patients with T2DM was associated with significant reductions in A1C and weight after 1 year of therapy. This was offset, however, by an exenatide discontinuation rate of 36%, primarily due to adverse gastrointestinal effects.
Authors:
Catherine A Sheffield; Michael P Kane; Robert S Busch; Gary Bakst; Jill M Abelseth; Robert A Hamilton
Related Documents :
11172324 - Attaining long-term survival when treating diabetic patients with esrd by hemodialysis.
20108584 - Molecular mechanisms behind clinical benefits of intensive insulin therapy during criti...
17658964 - The pharmacist's role in maintaining adherence to insulin therapy in type 2 diabetes me...
25187374 - Genome-wide association meta-analysis identifies novel variants associated with fasting...
7743244 - The impact of acute lymphocytic leukemia on diabetic retinopathy.
20406654 - Effects of arecoline on adipogenesis, lipolysis, and glucose uptake of adipocytes-a pos...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists     Volume:  14     ISSN:  1934-2403     ISO Abbreviation:  Endocr Pract     Publication Date:  2008 Apr 
Date Detail:
Created Date:  2008-05-08     Completed Date:  2008-08-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9607439     Medline TA:  Endocr Pract     Country:  United States    
Other Details:
Languages:  eng     Pagination:  285-92     Citation Subset:  IM    
Affiliation:
Department of Pharmacy Practice, Albany College of Pharmacy The Endocrine Group, Albany, New York 12208, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abdominal Pain / chemically induced
Aged
Diabetes Mellitus, Type 2 / blood,  drug therapy*
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Hemoglobin A, Glycosylated / metabolism
Humans
Hypoglycemic Agents / adverse effects,  therapeutic use*
Insulin / adverse effects,  therapeutic use*
Male
Middle Aged
Nausea / chemically induced
Peptides / adverse effects,  therapeutic use*
Retrospective Studies
Treatment Outcome
Venoms / adverse effects,  therapeutic use*
Vomiting / chemically induced
Chemical
Reg. No./Substance:
0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Peptides; 0/Venoms; 11061-68-0/Insulin; 141732-76-5/exenatide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adrenal incidentalomas, 2003 to 2005: experience after publication of the National Institutes of Hea...
Next Document:  Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients...